By Helena Smolak
Germany's Merck KGaA is scheduled to report results for the first quarter on Thursday. Here is what you need to know.
SALES FORECAST: The pharmaceutical and chemicals group is expected to report net sales of 5.28 billion euros ($5.85 billion), according to consensus estimates compiled by the company. For last year's first quarter, Merck reported sales of 5.12 billion euros.
EARNINGS FORECAST: Merck's earnings before interest, taxes, depreciation, amortization and one-off items is forecast to come in at 1.51 billion euros, according to the consensus. The company reported 1.45 billion for euros a year earlier.
In European early afternoon trading, shares were up 0.8%. They are down 9.9% since the start of the year.
WHAT TO WATCH
--The company will likely reiterate its full-year guidance, Morgan Stanley analysts said in a research note.
--Merck KGaA's life science and electronics sales could be skewed to the second half of the year, while healthcare sales should take a hit from U.S. competition to its cancer drug Bavencio, the analysts said.
--Investors will closely watch management's commentary around potential tailwinds from customer inventory build ahead of Trump's tariffs and its direct impact on its life science business, UBS analysts said in a note. Merck's broad network of U.S.-based manufacturing plants should limit the impact from import tariffs, the analysts said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 13, 2025 08:42 ET (12:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.